LongeVC
VC Fund
Lugano, Switzerland
LongeVC is a VC fund in Lugano focused on Health Care and Biotechnology. LongeVC was created to support early-stage biotech and longevity-focused founders on their way to gain industrial momentum, raise capital, and grow to become the shapers of tomorrow's biotech industry.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries LongeVC invests in
Stages LongeVC invests in
Countries LongeVC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.3M–$12M
- Series A
- $17M–$94M
Investment Focus
Industry
- Health Care 13 (59%)
- Biotechnology 13 (59%)
- Therapeutics 6 (27%)
- Artificial Intelligence 4 (18%)
- Life Science 3 (14%)
Stage
- Seed 10 (45%)
- Series A 7 (32%)
- Venture - Series Unknown 3 (14%)
- Pre-Seed 1 (5%)
- Funding Round 1 (5%)
Country
- United States 11 (50%)
- United Kingdom 4 (18%)
- Canada 1 (5%)
- Estonia 1 (5%)
- Hong Kong 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Garri Zmudze
Co-Founding Partner & Managing Partner
|
Co-Founding Partner & Managing Partner | Total investments: 9 | Find email | |
Ilya Suharenko
Managing Partner and Co-Founder
|
Managing Partner and Co-Founder | Total investments: 1 | Find email | |
Sergey Jakimov
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Valink Therapeutics is a health care drug discovery for next-generation cancer treatments. | $11.8M / Seed / Oct 20, 2025 | ||
| Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M / Series A / Oct 06, 2025 | ||
| Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | Venture - Series Unknown / Apr 03, 2025 | ||
| SiPhox offers a handheld testing device with RNA/DNA and protein testing for point-of-care and At-Home solutions. The company's kit is made by multiplexing RNA, antibody, and antigen tests on a single silicon photonic chip which is amplified by plasmon resonance and silicon photonic resonator readout, enabling users to undertake tests fordisease safely and in a disposable point-of-care and at-home manner.SiPhox was founded in 2020 and is based in Cambridge, Massachusetts, USA. | Series A / Mar 04, 2025 | ||
| Proton Intelligence provides biomarker monitoring to manage chronic disease and save lives. The first biomarker is potassium, targeting hyperkalemia in chronic kidney disease (CKD) patients who have additional co-morbidities ProtonIntel was founded in 2020 and was headquartered in Vancouver, Canada. | $7M / Seed / Dec 24, 2024 | ||
| We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biologyand disease. | Seed / Nov 25, 2024 | ||
| Melio provides a quick and comprehensive blood test that detects all prevalent infections. Their technology allows for prompt and targeted therapy while also combating antibiotic resistance. Melio is headquartered in Santa Clara, California. | $4M / Seed / Jun 30, 2024 | ||
| Catena Biosciences is a biotechnology company that offers protein conjugation, building biologic structures, and medical research. | $2.4M / Seed / May 10, 2024 | ||
| Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $40M / Series A / Apr 22, 2024 | ||
| Ani Biome is a longevity biotech startup that has the mission of optimizing and enhancing one's mind | Seed / Mar 03, 2024 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does LongeVC invest in?
LongeVC invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does LongeVC invest in?
LongeVC typically joins rounds of $1.3M–$12M at Seed and $17M–$94M at Series A. These are whole funding-round sizes, not LongeVC's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds LongeVC took part in.
How do I contact LongeVC?
Public channels for LongeVC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LongeVC?
The team at LongeVC includes Garri Zmudze (Co-Founding Partner & Managing Partner), Ilya Suharenko (Managing Partner and Co-Founder) and Sergey Jakimov (Co-Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
